Allianz Asset Management
RAPP

Allianz Asset Management’s Rapport Therapeutics RAPP Stock Holding History

Allianz Asset Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Sell
10,700
-2,500
-19% -$91.9K ﹤0.01% 2009
2026
Q1 		$413K Hold
13,200
– – ﹤0.01% 1862
2025
Q4 		$400K Buy
+13,200
New +$365K ﹤0.01% 1864

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Allianz Asset Management's RAPP Position: Q2 2026 in Review

Allianz Asset Management reduced its Rapport Therapeutics (RAPP) stake by 19% in Q2 2026, selling an estimated $91.9K and leaving 10,700 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #2009.

Allianz Asset Management first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Allianz Asset Management held 10,700 shares of Rapport Therapeutics worth $446K as of Q2 2026.
  • Allianz Asset Management sold 2,500 Rapport Therapeutics shares in Q2 2026, an estimated $91.9K.
  • Rapport Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2009 holding.
  • Allianz Asset Management first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.